Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …

Stroke is a leading cause of morbidity and mortality in the United States. Whether
hemorrhagic or ischemic, stroke leads to severe long-term disability. Prior to the mid-1990s …

Importance Recanalization of intracranial thrombus is associated with improved clinical
outcome in patients with acute ischemic stroke. The association of intravenous alteplase …

Importance Symptomatic intracranial hemorrhage (sICH) is a serious complication of stroke
thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of …

Importance Microvascular obstruction commonly affects patients with acute ST-segment
elevation myocardial infarction (STEMI) and is associated with adverse outcomes. Objective …

Introduction In recent years, as one of the drugs for the treatment of acute ischemic stroke
(AIS), the clinical application of tenecteplase is still controversial. Therefore, we aimed to …

Background Tenecteplase has potential benefits over alteplase, the standard agent for
intravenous thrombolysis in acute ischaemic stroke, because it is administered as a single …

Background: Prior systematic reviews have compared the efficacy of intravenous
tenecteplase and alteplase in acute ischemic stroke, assigning their relative complications …

Intravenous thrombolysis is a standard of care treatment for patients with acute ischemic
stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since …

Background Intravenous thrombolysis is considered to be the standard reperfusion therapy
for acute ischemic stroke, but its application is limited by high risk of hemorrhagic …